. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Epilepsia. 2015 Jul 3;56(8):1275–1285. doi: 10.1111/epi.13056

Table 3. Analysis of practice variability, age, status epilepticus severity, and outcome association regarding first-line treatment dosage adequacy for clonazepam, lorazepam, and midazolam.

		CLZ		p-Value (test)	LZP		p-Value (test)	MDZ

		Adequate dose	Insufficient dose		Adequate dose	Insufficient dose		Adequate dose	Insufficient dose	p-Value (test)
N		52	20		10	72		11	12
Center	n (%)
CHUV		52 (72.22)^a	20 (27.78)^a		0 (0)^a	0 (0)^a		11 (57.89) ^a	8 (42.11)^a
BWH		0 (0)	0 (0)		8 (16)	42 (84)		0 (0)	2 (100)
MGH		0 (0)	0 (0)		1 (4.17)	23 (95.83)		0 (0)	1 (100)
BIDMC		0 (0)	0 (0)	n/a	1 (12.5)	7 (87.5)	0.34 (Fisher)	0 (0)	1 (100)	0.205 (Fisher)
Age	Mean (SD)	57.6 (21.7)	64.9 (21.3)	0.2 (t-test)	46.1 (11.9)	57 (16.6)	0.04 (t-test)	46.5 (27.7)	57 (17.1)	0.28 (t-test)
STESS	Mean (SD)	2.86 (1.53)	2.6 (1.95)	0.54 (t-test)	2.2 (0.42)	2.38 (1.78)	0.74 (t-test)	2.36 (1.2)	3 (1.16)	0.16 (t-test)
Refractory SE	n (%)	25 (48.8)^b	6 (30)^b	0.165 (χ²)	6 (60)^b	62 (86.1)^b	0.04 (χ²)	4 (36.36)^b	5 (41.67)^b	0.795 (χ²)
Number of ASD	n (%)
0–2		23 (44.23)^b	13 (65)^b		3 (30)^b	10 (13.9)^b		5 (45.45)^b	6 (50)^b
3–4		23 (44.23)	6 (30)		5 (50)	42 (58.33)		6 (54.44)	2 (16.67)
≥5		6 (11.54)	1 (5)	0.362 (Fisher)	2 (20)	20 (27.78)	0.47 (Fisher)	0 (0)	4 (33.33)	0.07 (Fisher)
Mortality		4 (7.69)^b	4 (20)^b	0.137 (χ²)	1 (10)^b	10 (13.89)^b	1 (Fisher)	0 (0)^b	1 (8.33)^b	1 (Fisher)

ASD, antiseizure drug; BIDMC, Beth Israel Deaconess Medical Center; BWH, Brigham and Women's Hospital; CHUV, Centre Hospitalier Universitaire Vaudois; MGH, Massachusetts General Hospital; SD, standard deviation; STESS, STatus Epilepticus Severity Score.

In Bold: statistically significant.

Raw percentage.

Column percentage.